Abstract

This study will determine if a drug called sirolimus is safe to give to people with geographic atrophy GA and if it can help preserve vision in patients. GA is an advanced form of dry age-related macular degeneration (AMD). AMD affects the macula, the central part of the retina needed for sharp, clear vision. There are two types of AMD, wet and dry. In dry AMD, cells in the macula die.GA may at least partly be caused by inflammation. Sirolimus helps prevent inflammation and therefore may help treat GA.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIAEY000495-02
Application #
8339803
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2011
Total Cost
$114,724
Indirect Cost

  Institution

Name
U.S. National Eye Institute
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Wong, Wai T; Dresner, Samuel; Forooghian, Farzin et al. (2013) Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial. Invest Ophthalmol Vis Sci 54:2941-50
Meleth, Annal D; Mettu, Pradeep; Agron, Elvira et al. (2011) Changes in retinal sensitivity in geographic atrophy progression as measured by microperimetry. Invest Ophthalmol Vis Sci 52:1119-26
Wong, Wai T; Kam, Waynekid; Cunningham, Denise et al. (2010) Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial. Invest Ophthalmol Vis Sci 51:6131-9